The ongoing mission of the Michigan Cancer Research Consortium (MCRC) is to improve the oncologic health of the communities served by assuring patient access and participation in state-of-the-art clinical trials and cancer prevention and control activities while contributing to knowledge development in the field of oncology care. The MCRC represents a proven resource with significant potential to serve the objectives of the National Cancer Institute's CCOP program. First funded in 1994 as a single component CCOP, it is now comprised of thirteen health systems and 150+ investigators from 53 practices, covering the southeast quadrant of Michigan and Hartford, CT. Annual accrual approaches 500+ credits to cancer treatment and prevention/control trials. There are currently 2,600+ patients in follow-up. This grant application encompasses and articulates a vision for the MCRC that places community research on the cutting edge of cancer care. The development of biospecimen repositories and the movement to targeted therapies are only two initiatives with which we are involved. During the previous grant cycle, the MCRC proved a leader in the development of a network of component hospitals that is no longer reliant on geographic adjacencies. Rather, the MCRC utilized today's technology (e.g., websites, internet) to develop systems that facilitate the work of the CCOP with efficiency and ease irrespective of location. Of importance during this upcoming grant cycle will be the MCRC's leadership in working with the NCI to streamline the implementation of systems and processes that impact community research (e.g., consolidation of research bases). Support of and participation in NCI efforts to revamp the clinical trials network in order to expand translational research and facilitate collaborative team science is vital to MCRC's future.

Public Health Relevance

The Community Clinical Oncology Program (CCOP) links community cancer specialists, primary care physicians, and other health care professionals to the NCI-supported Cooperative Groups and Cancer Centers to conduct NCI-approved cancer treatment, prevention, and control clinical trials. The MCRC is the largest CCOP in the state of Michigan serving the adult population.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA063848-19
Application #
8305836
Study Section
Special Emphasis Panel (ZCA1-SRLB-E (J1))
Program Officer
Whitman, Cynthia B
Project Start
1994-08-05
Project End
2015-05-31
Budget Start
2012-08-14
Budget End
2013-05-31
Support Year
19
Fiscal Year
2012
Total Cost
$1,350,305
Indirect Cost
$404,866
Name
Saint Joseph Mercy Health System
Department
Type
DUNS #
807606249
City
Ann Arbor
State
MI
Country
United States
Zip Code
48106
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Liu, Xiaonan; Li, Jing; Wu, Teresa et al. (2016) Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade ≥ 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol 5:
Neal, Joel W; Dahlberg, Suzanne E; Wakelee, Heather A et al. (2016) Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol 17:1661-1671
Crozier, Jennifer A; Advani, Pooja P; LaPlant, Betsy et al. (2016) N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy. Clin Breast Cancer 16:23-30
Park, Haeseong; Qin, Rui; Smith, Thomas J et al. (2015) North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause 22:627-32
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Rule, William G; Foster, Nathan R; Meyers, Jeffrey P et al. (2015) Prophylactic cranial irradiation in elderly patients with small cell lung cancer: findings from a North Central Cancer Treatment Group pooled analysis. J Geriatr Oncol 6:119-26
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62

Showing the most recent 10 out of 148 publications